Tobraz 80mg (Tobramycin)

Adult dosage

In the case of severe infections, Tobramycin is administered intravenously or intramuscularly at 3mg (potency) per kg of body weight divided into 3 doses per day. In life-threatening infections, it may be administered up to 5mg (potency) per kg of body weight in 3 to 4 divided doses. If symptoms improve, the dosage should be reduced to 3mg (potency) per kg of body weight. It should not be administered in excess of 5mg (potency) per kg of body weight per day without serum concentration testing.

Children's dosage

In children, 5mg (potency) per kg of body weight is administered intravenously or intramuscularly in 3 to 4 divided doses per day. For neonates (under 1 week old), 4mg (potency) per kg of body weight is divided and administered every 12 hours.

This medication should not be used in certain patients. For example, patients who are allergic to this medication or to aminoglycoside antibiotics, bacitracin, those with inner ear and middle ear disease, severe renal impairment, pregnant or nursing women, those with muscle disorders, patients with bronchial asthma, and patients with disorders of the eighth cranial nerve should not be administered this drug. Additionally, this drug should be used cautiously in some patients. Patients with a family history of hearing loss, impaired kidney or liver function, premature infants or newborns, elderly patients, those unable to take orally, and individuals allergic to sulfites need to exercise caution. When using this medication, rare gastrointestinal symptoms such as shock, nausea, vomiting, loss of appetite, and diarrhea, as well as blood abnormalities, dizziness, tinnitus, and hearing loss may occur; hence, symptoms should be monitored closely. It can affect liver and kidney function, so regular testing is required. If skin rashes or hypersensitivity occur, administration should be stopped immediately. To prevent the emergence of resistant bacteria, sensitivity testing is recommended, and it should only be used for the necessary minimum duration. Moreover, to prevent hearing and kidney damage, it is advisable to limit the duration of administration to less than 10 days, and monitoring of blood concentration and hearing tests are recommended. Patients with mitochondrial genome mutations are at increased risk of ototoxicity and may need to consider alternative treatment options. This medication should be used with caution when taken alongside other nephrotoxic drugs, muscle relaxants, or anesthetics, and may affect blood coagulation, so the risk of bleeding should be monitored when used with anticoagulants. During pregnancy, it should be used cautiously as it can cause nerve damage to the newborn, and during breastfeeding, administration should be stopped. Newborns or premature infants may have immature kidney function, resulting in increased drug concentration, so dosing intervals should be adjusted. Elderly patients are at increased risk of side effects due to reduced kidney function, so care should be taken with dosing and intervals. In case of overdose, symptoms such as renal impairment, hearing damage, and respiratory distress may arise, requiring appropriate dialysis treatment and symptom-based care. Additionally, mixing this medication with beta-lactam antibiotics for injection can reduce efficacy, so administration via different routes is necessary. Lastly, patients who have received large-volume blood transfusions may be at risk of neuromuscular blockade and respiratory paralysis, thus requiring caution.

Serious side effects

Hives, severe swelling (edema), bronchial asthma, shock, acute renal failure, jaundice, toxic epidermal necrolysis, Stevens-Johnson syndrome, severe allergic reactions, severe skin reactions, respiratory issues, liver abnormalities, eighth cranial nerve disorders (dizziness, tinnitus, hearing loss, etc.), severe neurological symptoms, severe edema or urination abnormalities, respiratory depression, respiratory paralysis

Mild side effects

• Nausea
• vomiting
• loss of appetite
• stomatitis
• diarrhea
• anemia
• leukopenia
• leukocytosis
• granulocytosis
• eosinophilia

This medication should be stored in a sealed container that prevents air or moisture from entering. It is advisable to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance

A vial injection containing a colorless and transparent liquid

Package unit

1 vial (2mL) X 10